Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep;97(36):e12230.
doi: 10.1097/MD.0000000000012230.

Cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis

Xiang Wang  1 , Song Tang, Xiang Cui, Jinwei Yang, Chunyu Geng, Cong Chen, Ning Zhou, Yumin Li
Affiliations
Review

Cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer: A systematic review and meta-analysis

Xiang Wang et al. Medicine (Baltimore). 2018 Sep.

Abstract

Background: Immunotherapy is emerging as a new treatment strategy for gastric cancer(GC). However, the efficacy and safety of this technique remain unclear. This meta-analysis aimed to assess the effect of cytokine-induced killer cell (CIK)/dendritic cell-cytokine-induced killer cell (DC-CIK) treatment for GC after surgery.

Methods: Hazard ratio (HR), overall survival (OS) rates, and disease-free survival (DFS) rates were calculated using a Mantel-Haenszel (M-H) fixed-effects model (FEM), and results were displayed using forest plots. Publication bias was assessed by Begg test, and data were presented using funnel plots. Date robustness was assessed by the trim and fill method. Descriptive analysis was performed on T lymphocytes and adverse effects.

Results: In total, 9 trials, including 1216 patients, were eligible for inclusion in this meta-analysis. Compared with the control group, the HR for OS was 0.712 (95% confidence interval [CI] 0.594-0.854) and 0.66 (95% CI 0.546-0.797) for overall (DFS). The risk ratio (RR) of the 3 and 5-year OS rate was 1.29 (95% CI 1.15-1.46) and 1.73 (95% CI 1.36-2.19), respectively. The RR for the 3 and 5-year DFS rate 1.40 (95% CI 1.19-1.65) and 2.10 (95% CI1.53-2.87), respectively. The proportion of patients who were CD3+, CD4+, and CD4+/CD8+ increased in the cellular therapy groups. No fatal adverse reactions were noted.

Conclusion: Chemotherapy combined with CIK/DC-CIK therapy after surgery resulted in low HR, and significantly increasing OS rates, DFS rates, and T-lymphocyte responses in patients with GC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing financial interests.

Figures

Figure 1
Figure 1
Search strategy.
Figure 2
Figure 2
Selection procedure used to identify clinical trials.
Figure 3
Figure 3
(A) Forest plot of hazard ratio (HR) for overall survival; (B) forest plot of HR for overall disease-free survival.
Figure 4
Figure 4
Forest plot of overall survival and disease-free survival for treatment and control groups over 3 and 5-year periods.
Figure 5
Figure 5
(A) Funnel plot of HR for the overall survival; (B) funnel plot of HR for overall disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Biondi A, Persiani R, Cananzi F, et al. R0 resection in the treatment of gastric cancer: room for improvement. World J Gastroenterol 2010;16:3358–70. - PMC - PubMed
    1. Sastre J, Garcia-Saenz JA, Diaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006;12:204–13. - PMC - PubMed
    1. DeFrancesco L. Landmark approval for Dendreon's cancer vaccine. Nat Biotechnol 2010;28:531–2. - PubMed
    1. Chen B, Liu L, Xu H, et al. Effectiveness of immune therapy combined with chemotherapy on the immune function and recurrence rate of cervical cancer. Exp Ther Med 2015;9:1063–7. - PMC - PubMed
    1. Zhu XP, Xu YH, Zhou J, et al. A clinical study evaluating dendritic and cytokine-induced killer cells combined with concurrent radiochemotherapy for stage IIIB non-small cell lung cancer. Genet Mol Res 2015;14:10228–35. - PubMed

MeSH terms

Substances